Watch MPLT. Know when insiders buy.
One email the day a filing lands. Free.
MPLT
MapLight Therapeutics, Inc.
10.92
−0.40 −3.53%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · insiders 41, shorts 36
Insiders, 90 days
−$193K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $463.4MP/E 0.2DIV YIELD —FCF YIELD -37.79%REV TTM —NET INCOME −$229.8MNET CASH —52W 9.90 – 39.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$63.5M | −$60.2M | — | -1.32 | −$44.9M | $22K | −$44.9M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$64.5M | −$60.7M | — | -1.34 | −$51.2M | $24K | −$51.2M | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$83.4M | −$79.5M | — | 87.14 | −$46.8M | $376K | −$47.2M | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$31.5M | −$29.4M | — | -37.18 | −$31.8M | $31K | −$31.8M | Dec 4 |
| Q2 2025 · Jun 30 | — | — | — | −$30.7M | −$29.8M | — | -39.11 | −$34M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$23.5M | −$22.3M | — | -29.33 | −$25.6M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$22.8M | −$21.2M | — | -28.01 | −$21.5M | $106K | −$21.6M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$20.9M | −$19M | — | -25.08 | — | — | — | Dec 4 |
| Q2 2024 · Jun 30 | — | — | — | — | −$18.4M | — | — | — | — | — | Dec 4 |
| Q1 2024 · Mar 31 | — | — | — | — | −$18.9M | — | — | — | — | — | Dec 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$169.1M | −$161.2M | — | -18.56 | −$138.1M | $473K | −$138.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$82.9M | −$77.6M | — | -105.38 | −$78.8M | $770K | −$79.6M | — | — |
Every number comes from MapLight Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.